Editas Medicine Launches Shelf-Registered Offering of Common Stock and Warrants
EDIT•Editas Medicine has launched an underwritten offering of common shares (or pre-funded warrants) and accompanying warrants, with Cantor Fitzgerald and Wells Fargo Securities as joint book-running managers. The securities are to be sold under its March 2025 Form S-3 shelf registration, with completion and final terms subject to market conditions.
1. Offering Launch and Scope
Editas Medicine has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase common shares) and accompanying warrants. All securities in the offering are to be sold by Editas Medicine directly to investors.
2. Shelf Registration Background
The offering is being conducted pursuant to the company’s effective shelf registration statement on Form S-3 (declared effective March 21, 2025), allowing rapid access to capital through registered issuances of equity and warrant instruments.
3. Joint Book-Running Managers and Conditions
Cantor Fitzgerald and Wells Fargo Securities are acting as joint book-running managers for the proposed offering. Completion, size and pricing of the offering remain subject to market and customary closing conditions.
